Market Research Report
2021 Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: A Study of Biotherapeutic Developers and Contract Manufacturing Organizations, 18th Edition
|2021 Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: A Study of Biotherapeutic Developers and Contract Manufacturing Organizations, 18th Edition|
Published: April 30, 2021
BioPlan Associates, Inc.
Content info: 491 Pages
Delivery time: 1-2 business days
survey respondents included diverse biopharmaceutical and bioprocessing senior managers, executives and scientists covering a spectrum involved in biopharmaceutical development and manufacturing, including those within CMOs.
This is an international project done annually, with this now the 18th year edition. We solicit and receive survey responses from individuals at organizations around the world. This year includes input from individuals based in 25 countries.
In addition, in Chapter 12, we separately present responses from bioprocessing suppliers and vendors. As in previous years, responses are from companies of all sizes and types worldwide. Respondents have a broad range of responsibilities, but all respondents had to qualify as involved with bioprocessing/manufacturing in some way.
The diversity of survey respondents supports providing a comprehensive view of the industry from those most involved in managing biopharmaceutical manufacturing activities worldwide. Resulting survey data offer a means for understanding the industry and its future course. The breakdown of results by organization class, such as CMOs vs. biotherapeutic manufacturers/ therapeutic developers, provides further insights into major segments of the industry. These two types of organizations have different business drivers, risk profiles, costs of capital, etc.
For this year's 2021 survey, we asked in which area of biopharmaceutical manufacturing is your organization currently involved.
Of the 147 biopharmaceutical manufacturers and contract manufacturing organizations responding to this year's survey, 24.5% were primarily involved in "Process development for biopharmaceutical manufacturing," down from 29.2% in 2020, but overall consistent with previous year trends. 19.7% were primarily involved in "Large-scale cell culture production for therapeutics," down 10 percentage points from 29.2% in 2020. In past years, we have seen this % hovering in the 20s.
Overall, we see decreases this year in the top three areas, but increases in other categories. Respondents involved with "Large-scale contract manufacturing (CMO) for biopharmaceuticals" increased to 9.5%, up from 9.2% in 2020. "Large-scale microbial fermentation for therapeutics" respondents were at 8.8% this year, up five percentage points from 3.8% in 2020.
Tony Hsiao currently serves as the Senior Product Manager for Single-Use Technologies in Thermo Fisher Scientific's Bioproduction group. His focus is on new product development for bioprocessing customers. He also drives the addition of novel bioprocessing technologies and alternative applications to expand utility across our product platforms. He holds a Ph.D. and M.S. in Biomedical Engineering from the University of Utah, and a B.S. in Chemical Engineering from Brigham Young University.
Maik W. Jornitz, President and CEO of G-CON Manufacturing Inc., is a technical expert with over 30 years of experience in bioprocesses, especially sterilizing grade filtration and single-use technologies, including regulatory requirements, integrity testing, systems design, and optimization. Jornitz has published 11 books, 18 book chapters and over 100 scientific papers. He is the former Chair of the PDA Board of Directors and Science Advisory Board, and member of multiple PDA Task Forces.
Dr. Stefan R. Schmidt currently serves as COO/Head of Operations at BioAtrium AG, a Lonza and Sanofi JV in Switzerland. Previously he held the position as CSO and other senior executive roles at Rentschler Biopharma with overall responsibilities for development, production, and innovation. Before that, he was CSO at ERA Biotech in Barcelona, directing the company's R&D efforts.
Dr. Christoph Winterhalter has 25 years of experience in Life Science and serves currently as Senior Vice President Business Development at AGC Biologics, a global biopharmaceutical CDMO with sites in US, EU, and Japan. Before that he was heading Business Development globally at Rentschler Biopharma with a strong contribution to the tremendous growth phase from 2013-2017 were sales more than tripled.